{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:48:29Z","timestamp":1780080509210,"version":"3.54.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ygyno.2015.12.027","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T09:00:35Z","timestamp":1451379635000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study"],"prefix":"10.1016","volume":"140","clinical-trial-number":[{"clinical-trial-number":"nct00866697","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01227928","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Philipp","family":"Harter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5998-3270","authenticated-orcid":false,"given":"Toby","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Imhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dearbhaile","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Stinnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh","family":"Jobanputra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.12.027_bb0005","unstructured":"American Cancer Society. Cancer Facts & Figures 2014. Available at: http:\/\/www.cancer.org\/acs\/groups\/content\/@research\/documents\/webcontent\/acspc-042151.pdf. (Accessed: February 4, 2015)"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-line therapy in ovarian cancer trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0030","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0040","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0045","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0055","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0060","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1126\/science.1252230","article-title":"Cancer suppression by the chromosome custodians, BRCA1 and BRCA2","volume":"343","author":"Venkitaraman","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2012.24","article-title":"Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer","volume":"307","author":"Hyman","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0070","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0075","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/annonc\/mdt394","article-title":"Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms","volume":"24","author":"Motzer","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0080","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","article-title":"Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes","volume":"29","author":"Xu","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0085","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.2354","article-title":"Fast and accurate genotype imputation in genome-wide association studies through pre-phasing","volume":"44","author":"Howie","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes","volume":"491","author":"1000 Genomes Project Consortium","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0095","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0100","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0105","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.0006-341X.1999.00997.x","article-title":"Genomic control for association studies","volume":"55","author":"Devlin","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0110","series-title":"Presented at the Asian Society of Gynecologic Oncology Conference (ASGO); Kyoto, Japan","article-title":"Pazopanib maintenance therapy in East Asian (EA) women with advanced epithelial ovarian cancer (AEOC): results of two clinical trials","author":"Kim","year":"2013"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1634\/theoncologist.2012-0028","article-title":"BRCAness: finding the Achilles heel in ovarian cancer","volume":"17","author":"Rigakos","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0120","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0125","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/annonc\/mdi367","article-title":"Non-enrolment of ovarian cancer patients in clinical trials: reasons and background","volume":"16","author":"Harter","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0130","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.027_bb0140","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2015.12.027_bb0145","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fFourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815302304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815302304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T13:36:11Z","timestamp":1620826571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815302304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0090825815302304"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}